What Is Multifocal Pneumonia? Here's What to Know, According to Doctors
pulmonary fibrosis stages :: Article Creator
Featured Post
Zynex (ZYXI) and Aradigm (NASDAQ:ARDM) Financial Survey - Fairfield Current
Zynex (OTCMKTS:ZYXI) and Aradigm (NASDAQ:ARDM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.
Valuation & Earnings
This table compares Zynex and Aradigm’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zynex | $23.43 million | 5.47 | $7.36 million | $0.22 | 17.50 |
| Aradigm | $14.47 million | 0.59 | -$10.70 million | ($0.72) | -0.78 |
Zynex has higher revenue and earnings than Aradigm. Aradigm is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Zynex and Aradigm’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zynex | 33.33% | 152.81% | 95.46% |
| Aradigm | -374.80% | N/A | -374.15% |
Volatility & Risk
Zynex has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Aradigm has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.
Insider & Institutional Ownership
0.1% of Zynex shares are owned by institutional investors. Comparatively, 30.0% of Aradigm shares are owned by institutional investors. 4.5% of Aradigm shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Zynex and Aradigm, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zynex | 0 | 0 | 1 | 0 | 3.00 |
| Aradigm | 0 | 0 | 0 | 0 | N/A |
Zynex currently has a consensus target price of $7.00, indicating a potential upside of 81.82%. Given Zynex’s higher possible upside, analysts clearly believe Zynex is more favorable than Aradigm.
Summary
Zynex beats Aradigm on 10 of the 13 factors compared between the two stocks.
Zynex Company Profile
Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Aradigm Company Profile
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.
http://bit.ly/2RXxWRC
Popular Posts
Preventing, controlling spread of animal diseases focus of forum at Penn State - Pennsylvania State University
UNIVERSITY PARK, Pa. — An outbreak of the highly pathogenic avian influenza virus in poultry in 2014-15 resulted in the destruction of more than 50 million chickens and turkeys in the U.S., causing billions of dollars in economic loss. This animal disease outbreak — the worst in U.S. history — is one example of how devastating a foreign animal disease can be to animal agriculture and the country's economy. The resurgence of avian influenza in multiple states, including Pennsylvania, is once again bringing the importance of preventing animal diseases to the forefront, noted Suresh Kuchipudi, clinical professor of microbiology in Penn State's College of Agricultural Sciences. Exploring the emergence, spread and control of animal infectious diseases such as avian influenza was the focus of the inaugural Emerging Animal Infectious Disease Conference held Nov. 29-Dec.1, 2021, at Penn State. It was hosted by the College of Agricultural Sciences, the Pennsylvania Department of A
Model Monday's: Diana Moldovan
dented can botulism :: Article Creator Three Canadians Sickened In France's Botulism Outbreak Are From Quebec: PHAC The Public Health Agency of Canada has confirmed that the three Canadians who fell ill in a botulism outbreak in France are from Quebec. They're among at least 12 people who have suspected botulism after eating sardines prepared and served at Tchin Tchin Wine Bar in Bordeaux, France. The food was eaten between Sept. 4 and Sept. 10. The Associated Press has reported that some patients have been released from hospital, but most of them are in intensive care or critical condition. Canada's public health agency says it cannot divulge the condition of the patients from Quebec because it is considered private health information. Other tourists from the U.S., Ireland, Germany and Spain were among those sickened. One patient, who was not from Canada, has died. France's public health agency is leading the investigation
“Live Coronavirus Map Used to Spread Malware - Krebs on Security” plus 1 more
“Live Coronavirus Map Used to Spread Malware - Krebs on Security” plus 1 more Live Coronavirus Map Used to Spread Malware - Krebs on Security Posted: 12 Mar 2020 05:12 PM PDT Cybercriminals constantly latch on to news items that captivate the public's attention, but usually they do so by sensationalizing the topic or spreading misinformation about it. Recently, however, cybercrooks have started disseminating real-time, accurate information about global infection rates tied to the Coronavirus/COVID-19 pandemic in a bid to infect computers with malicious software. A recent snapshot of the Johns Hopkins Coronavirus data map, available at coronavirus.jhu.edu. In one scheme, an interactive dashboard of Coronavirus infections and deaths produced by Johns Hopkins University is being used in malicious Web sites (and possibly spam emails) to spread password-stealing malware. Late last month, a member of several Russian language cybercr
Comments
Post a Comment